Explore

Trendline Trendline
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Targeting Rare Disease Market

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Targeting Rare Disease Market

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Targeting Rare Disease Market
Trendline Trendline
Neurocrine Biosciences Acquires Soleno Therapeutics in $2.9 Billion Deal, Expanding Rare Disease Portfolio

Neurocrine Biosciences Acquires Soleno Therapeutics in $2.9 Billion Deal, Expanding Rare Disease Portfolio

Neurocrine Biosciences Acquires Soleno Therapeutics in $2.9 Billion Deal, Expanding Rare Disease Portfolio
Trendline Trendline
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expanding Treatment Options for Prader-Willi Syndrome

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expanding Treatment Options for Prader-Willi Syndrome

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expanding Treatment Options for Prader-Willi Syndrome
Trendline Trendline
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expanding into Metabolic Disorders

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expanding into Metabolic Disorders

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expanding into Metabolic Disorders
Reuters Reuters
Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout

Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout

April 6 (Reuters) - Neurocrine Biosciences will acquire rare-disease drugmaker Soleno Therapeutics for $2.9 billion in cash, the companies said on Monday, marking the neuroscience-focused drugmaker's expansion into metabolic disorders.
Trendline Trendline
Netflix and Soleno Therapeutics Lead Premarket Stock Movements Amid Strategic Upgrades and Acquisitions

Netflix and Soleno Therapeutics Lead Premarket Stock Movements Amid Strategic Upgrades and Acquisitions

Netflix and Soleno Therapeutics Lead Premarket Stock Movements Amid Strategic Upgrades and Acquisitions
Trendline Trendline
Lucid Group Faces Vehicle Delivery Challenges Amid Supplier Issues

Lucid Group Faces Vehicle Delivery Challenges Amid Supplier Issues

Lucid Group Faces Vehicle Delivery Challenges Amid Supplier Issues
Reuters Reuters
US stock futures edge up as investors assess Mideast ceasefire prospects

US stock futures edge up as investors assess Mideast ceasefire prospects

April 6 (Reuters) - U.S. stock index futures inched higher on Monday, after the main indexes marked their biggest weekly jump in four months in the last session, as investors assessed prospects of an end to the Middle East conflict.
Trendline Trendline
Rosen Law Firm Alerts Soleno Therapeutics Investors to Securities Fraud Lawsuit Deadline

Rosen Law Firm Alerts Soleno Therapeutics Investors to Securities Fraud Lawsuit Deadline

Rosen Law Firm Alerts Soleno Therapeutics Investors to Securities Fraud Lawsuit Deadline
Trendline Trendline
FDA Decision on Replimune's RP1 Drug Could Signal Regulatory Direction for Biopharma

FDA Decision on Replimune's RP1 Drug Could Signal Regulatory Direction for Biopharma

FDA Decision on Replimune's RP1 Drug Could Signal Regulatory Direction for Biopharma
Trendline Trendline
Kessler Topaz Meltzer Check, LLP Alerts Soleno Therapeutics Investors to Securities Fraud Class Action

Kessler Topaz Meltzer Check, LLP Alerts Soleno Therapeutics Investors to Securities Fraud Class Action

Kessler Topaz Meltzer Check, LLP Alerts Soleno Therapeutics Investors to Securities Fraud Class Action
Trendline Trendline
Kessler Topaz Meltzer Check, LLP Files Securities Fraud Lawsuit Against Soleno Therapeutics

Kessler Topaz Meltzer Check, LLP Files Securities Fraud Lawsuit Against Soleno Therapeutics

Kessler Topaz Meltzer Check, LLP Files Securities Fraud Lawsuit Against Soleno Therapeutics